Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Exelixis, Inc. operates as a development-stage biotechnology company focuses on discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company offers medicines to treat and defeat kidney and thyroid cancer and advanced melanoma. Exelixis develops strategic alliances with pharmaceutical and biotechnology companies.
Website: exelixis.com



Growth: Pretty weak revenue growth rate 3.9%, there is slowdown compared to average historical growth rates 23.1%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +10.7%. On average the margin is decreasing unsteadily. Gross margin is high, +95.0%. In the last quarter the company did not beat the estimated EPS, -20.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 46.4% higher than minimum and 14.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 5.1% overvalued

Insiders: For the last 3 months insiders bought company shares on $2.5 mln (0.041% of cap.)

Key Financials (Download financials)

Ticker: EXEL
Share price, USD:  (-1.0%)21.9
year average price 21.43  


year start price 19.03 2023-05-08

min close price 18.78 2023-06-14

max close price 24.13 2023-12-28

current price 21.90 2024-05-06
Common stocks: 300 757 000

Dividend Yield:  0.0%
FCF Yield LTM: -2.4%
EV / LTM EBITDA: 28.7x
EV / EBITDA annualized: 42.2x
Last revenue growth (y/y):  3.9%
Last growth of EBITDA (y/y):  2.6%
Historical revenue growth:  23.1%
Historical growth of EBITDA:  ---
EV / Sales: 3.1x
Margin (EBITDA LTM / Revenue): 10.7%
Fundamental value created in LTM:
Market Cap ($m): 6 587
Net Debt ($m): -913
EV (Enterprise Value): 5 674
Price to Book: 3.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-01Zacks Investment Research

Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short

2024-04-30Zacks Investment Research

Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say

2024-04-25Zacks Investment Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

2024-04-09Zacks Investment Research

EXEL or REGN: Which Is the Better Value Stock Right Now?

2024-03-06Zacks Investment Research

EXEL vs. REGN: Which Stock Is the Better Value Option?

2024-02-27GuruFocus

Exelixis' Growth Trajectory Depends on Leading Innovations in Cancer Treatments

2024-02-12Zacks Investment Research

Exelixis (EXEL) Loses -10.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2024-02-09Zacks Investment Research

Down -10% in 4 Weeks, Here's Why You Should You Buy the Dip in Exelixis (EXEL)

2024-02-08Zacks Investment Research

EXEL or REGN: Which Is the Better Value Stock Right Now?

2024-02-08Zacks Investment Research

Exelixis (EXEL) Loses -11.72% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2024-04-30 2024-02-06 2023-11-01 2023-08-01 2023-05-09 2023-02-07 2022-11-01
acceptedDate 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 425M 480M 472M 470M 409M 424M 412M
costOfRevenue 21M 22M 19M 18M 14M 16M 15M
grossProfit 404M 458M 453M 452M 394M 408M 396M
grossProfitRatio 0.950 0.955 0.960 0.962 0.965 0.962 0.963
researchAndDevelopmentExpenses 228M 245M 333M 233M 234M 337M 199M
generalAndAdministrativeExpenses 114M 91M 138M 0 0 0 0
sellingAndMarketingExpenses 0 40M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 114M 131M 138M 142M 131M 119M 115M
otherExpenses -89 000 -137 000 289 000 18M -54 000 -337 000 0
operatingExpenses 342M 376M 471M 392M 366M 456M 314M
costAndExpenses 363M 398M 490M 392M 380M 472M 329M
interestIncome 20M 21M 23M 23M 20M 17M 9M
interestExpense 0 26M 0 0 -26M -11M 9M
depreciationAndAmortization 6M 7M 6M 6M 7M 6M 6M
ebitda 102M 88M -18M 78M 29M -48M 88M
ebitdaratio 0.239 0.184 -0.037 0.166 0.071 -0.113 0.214
operatingIncome 29M 82M -18M 78M 22M -48M 83M
operatingIncomeRatio 0.069 0.171 -0.037 0.166 0.054 -0.113 0.201
totalOtherIncomeExpensesNet -33M -137 000 289 000 23M 26M 17M 9M
incomeBeforeTax 49M 103M 6M 100M 48M -31M 92M
incomeBeforeTaxRatio 0.116 0.215 0.012 0.214 0.118 -0.074 0.224
incomeTaxExpense 12M 18M 5M 19M 8M -1M 19M
netIncome 37M 86M 1M 81M 40M -30M 73M
netIncomeRatio 0.088 0.178 0.002 0.173 0.098 -0.071 0.178
eps 0.120 0.280 0.003 0.250 0.120 -0.093 0.230
epsdiluted 0.120 0.270 0.003 0.250 0.120 -0.093 0.230
weightedAverageShsOut 301M 308M 315M 324M 324M 323M 322M
weightedAverageShsOutDil 306M 313M 319M 327M 326M 323M 325M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2024-04-30 2024-02-06 2023-11-01 2023-08-01 2023-05-09 2023-02-07 2022-11-01
acceptedDate 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 260M 263M 397M 464M 541M 501M 675M
shortTermInvestments 704M 732M 707M 802M 773M 807M 872M
cashAndShortTermInvestments 963M 995M 1 103M 1 267M 1 313M 1 308M 1 547M
netReceivables 241M 237M 248M 233M 234M 215M 215M
inventory 21M 17M 25M 29M 30M 33M 27M
otherCurrentAssets 67M 68M 67M 62M 61M 62M 53M
totalCurrentAssets 1 292M 1 318M 1 443M 1 591M 1 638M 1 619M 1 842M
propertyPlantEquipmentNet 457M 471M 427M 419M 406M 401M 108M
goodwill 64M 64M 64M 64M 64M 64M 64M
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 64M 64M 64M 64M 64M 64M 64M
longTermInvestments 630M 729M 812M 839M 807M 757M 552M
taxAssets 362M 361M 231M 231M 230M 231M 116M
otherNonCurrentAssets 0 0 0 0 0 0 280M
totalNonCurrentAssets 1 511M 1 624M 1 534M 1 552M 1 506M 1 453M 1 120M
otherAssets 0 0 0 0 0 0 0
totalAssets 2 804M 2 942M 2 977M 3 142M 3 143M 3 071M 2 961M
accountPayables 26M 34M 26M 26M 33M 33M 31M
shortTermDebt -4M 26M -7M 196M 0 0 0
taxPayables 0 0 0 0 0 0 0
deferredRevenue 4M 5M 7M 7M 6M 7M 0
otherCurrentLiabilities 347M 329M 350M 111M 289M 285M 271M
totalCurrentLiabilities 373M 394M 377M 340M 328M 324M 302M
longTermDebt 201M 190M 191M 195M 187M 190M 160M
deferredRevenueNonCurrent 5M 6M 6M 7M 6M 7M 6M
deferredTaxLiabilitiesNonCurrent -5M 54M -6M 0 0 0 0
otherNonCurrentLiabilities 101M 35M 62M 73M 67M 62M 138M
totalNonCurrentLiabilities 303M 284M 252M 275M 261M 259M 168M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 201M 190M 191M 195M 187M 190M 160M
totalLiabilities 676M 678M 629M 615M 588M 583M 470M
preferredStock 2.000 0 14M 0 0 0 0
commonStock 295 000 303 000 311 000 320 000 325 000 324 000 323 000
retainedEarnings -259M -173M -126M 11M 6M -34M -4M
accumulatedOtherComprehensiveIncomeLoss -5M -4M -14M -14M -9M -15M -18M
othertotalStockholdersEquity 2 392M 2 441M 2 473M 2 531M 2 558M 2 537M 2 513M
totalStockholdersEquity 2 128M 2 264M 2 348M 2 528M 2 555M 2 488M 2 491M
totalEquity 2 128M 2 264M 2 348M 2 528M 2 555M 2 488M 2 491M
totalLiabilitiesAndStockholdersEquity 2 804M 2 942M 2 977M 3 142M 3 143M 3 071M 2 961M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 804M 2 942M 2 977M 3 142M 3 143M 3 071M 2 961M
totalInvestments 1 333M 1 461M 1 518M 1 641M 1 579M 1 564M 1 423M
totalDebt 201M 190M 191M 195M 187M 190M 160M
netDebt -58M -73M -206M -270M -354M -311M -515M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-29 2023-12-29 2023-09-29 2023-06-30 2023-03-31 2022-12-30 2022-09-30
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2024-04-30 2024-02-06 2023-11-01 2023-08-01 2023-05-09 2023-02-07 2022-11-01
acceptedDate 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 37M 86M 1M 81M 40M -30M 73M
depreciationAndAmortization 6M 7M 6M 6M 7M 6M 6M
deferredIncomeTax 0 -133M -23M -37M 0 -60M 0
stockBasedCompensation 19M 24M 40M 25M 17M 26M 37M
changeInWorkingCapital -29M 24M -25M 5M -19M 27M -15M
accountsReceivables -3M 11M -15M 861 000 -19M -41 000 20M
inventory 2M 2M -2M -4M -8M -2M -2M
accountsPayables -34M 47M 192 000 5M 1M 19M -11M
otherWorkingCapital 6M -35M -8M 3M 8M 9M -22M
otherNonCashItems 35M 3M 118M 40M 39M 106M 9M
netCashProvidedByOperatingActivities 69M 11M 117M 121M 84M 74M 110M
investmentsInPropertyPlantAndEquipment -18M -13M -94M -7M -49M -112M -8M
acquisitionsNet 0 -75M -129M 2M 49M 138M 0
purchasesOfInvestments -138M -79M -183M -329M -312M -371M -387M
salesMaturitiesOfInvestments 268M 153M 311M 263M 311M 238M 326M
otherInvestingActivites 121M 75M 129M -2M -49M -138M 0
netCashUsedForInvestingActivites 112M 62M 35M -74M -50M -246M -69M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 8M 9M 7M 10M 7M 8M 0
commonStockRepurchased -185M -209M -217M 10M 0 24M 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites -7M -6M -10M -145M -3M -34M -2M
netCashUsedProvidedByFinancingActivities -184M -206M -220M -125M 5M -2M -2M
effectOfForexChangesOnCash 0 -123M 0 123M 0 0 0
netChangeInCash -3M -134M -68M -78M 39M -174M 39M
cashAtEndOfPeriod 260M 263M 397M 464M 542M 503M 677M
cashAtBeginningOfPeriod 263M 397M 464M 542M 503M 677M 638M
operatingCashFlow 69M 11M 117M 121M 84M 74M 110M
capitalExpenditure -18M -13M -94M -7M -49M -112M -8M
freeCashFlow 51M -3M 23M 114M 36M -39M 102M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-04-30 20:05 ET
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
2024-04-16 20:05 ET
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
2024-02-27 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
2024-02-06 21:05 ET
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
2024-02-01 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
2024-01-25 13:00 ET
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
2024-01-23 21:05 ET
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
2024-01-18 21:05 ET
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
2024-01-07 21:00 ET
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
2024-01-02 21:05 ET
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
2023-12-07 21:05 ET
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
2023-12-04 13:02 ET
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
2023-11-21 21:05 ET
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
2023-11-10 14:00 ET
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
2023-11-01 20:05 ET
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-22 06:30 ET
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
2023-10-18 20:05 ET
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
2023-09-12 12:00 ET
Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor
2023-08-31 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
2023-08-24 12:00 ET
Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors
2023-08-23 20:30 ET
Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
2023-08-21 05:00 ET
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
2023-08-01 20:05 ET
Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-23 20:00 ET
Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc.
2023-07-18 20:05 ET
Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
2023-05-31 16:30 ET
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis’ Board
2023-05-30 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
2023-05-09 20:05 ET
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
2023-05-08 03:30 ET
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
2023-05-07 21:00 ET
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
2023-05-03 20:05 ET
Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023
2023-05-03 13:00 ET
Farallon Capital Urges Exelixis Shareholders to Support Change by Electing Its Three Highly Qualified Director Candidates
2023-05-01 21:08 ET
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
2023-04-25 20:05 ET
Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
2023-04-13 20:11 ET
Exelixis Advances Board Refreshment Plan
2023-04-05 22:06 ET
Exelixis Reiterates Commitment to Shareholder Value Creation
2023-04-05 12:00 ET
Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change
2023-03-20 11:00 ET
Exelixis Announces $550 Million Share Repurchase Program
2023-03-13 20:05 ET
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
2023-03-02 22:30 ET
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
2023-02-28 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
2023-02-13 22:00 ET
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
2023-02-13 13:00 ET
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
2023-02-07 21:05 ET
Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-02-02 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
2023-01-24 21:05 ET
Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023
2023-01-19 23:43 ET
Exelixis Announces Update on Patent Litigation with MSN Laboratories
2023-01-08 21:00 ET
Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023
2023-01-03 21:05 ET
Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023 —  Presentation to be webcast on www.exelixis.com  —
2022-12-22 13:00 ET
Exelixis Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer
2022-12-08 21:05 ET
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
2022-12-08 13:00 ET
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
2022-11-30 21:05 ET
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
2022-11-10 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
2022-11-03 12:00 ET
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
2022-11-01 20:07 ET
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
2022-11-01 20:06 ET
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
2022-11-01 20:05 ET
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
2022-10-26 08:00 ET
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
2022-10-18 20:05 ET
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
2022-10-04 12:00 ET
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
2022-09-10 07:00 ET
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
2022-09-07 22:05 ET
Exelixis Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022
2022-09-06 20:05 ET
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in September
2022-08-09 20:05 ET
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
2022-07-26 20:05 ET
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
2022-07-11 12:00 ET
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
2022-07-07 04:00 ET
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
2022-07-05 20:05 ET
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
2022-06-21 12:00 ET
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
2022-06-16 04:00 ET
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
2022-05-31 20:05 ET
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
2022-05-26 21:00 ET
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
2022-05-26 21:00 ET
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
2022-05-10 20:05 ET
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-04 20:05 ET
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
2022-05-03 12:00 ET
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2022-04-26 20:05 ET
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
2022-04-14 12:00 ET
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
2022-04-13 20:05 ET
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
2022-03-25 12:49 ET
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2022-03-14 20:05 ET
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
2022-03-02 21:05 ET
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in March
2022-02-17 21:05 ET
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2022-02-14 22:00 ET
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
2022-02-03 21:05 ET
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
2022-02-02 21:05 ET
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
2022-01-18 22:30 ET
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
2022-01-09 21:00 ET
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
2022-01-06 13:00 ET
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
2022-01-05 13:00 ET
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
2022-01-04 21:05 ET
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
2022-01-04 13:00 ET
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
2021-12-17 13:00 ET
Exelixis Elects Jacqueline Wright to Its Board of Directors
2021-12-15 13:00 ET
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
2021-11-20 11:00 ET
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
2021-11-09 13:00 ET
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
2021-11-03 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
2021-11-02 20:05 ET
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
2021-10-19 20:05 ET
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
2021-10-14 12:30 ET
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
2021-10-14 12:00 ET
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
2021-10-14 12:00 ET
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
2021-09-20 15:30 ET
Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021
2021-09-18 11:30 ET
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
2021-09-17 20:23 ET
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2021-09-16 06:30 ET
Exelixis Announces CABOMETYX® in Combination with OPDIVO® Provides Efficacy Benefits Regardless of Prior Nephrectomy in Patients with Previously Untreated Advanced Renal Cell Carcinoma Based on CheckMate -9ER Analysis Presented at ESMO 2021
2021-09-06 17:00 ET
Exelixis Statement on the Passing of Two Senior Executives
2021-09-01 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
2021-08-25 20:05 ET
Exelixis Announces Partner Takeda and Ono Receive Approval in Japan for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma
2021-08-16 12:05 ET
Exelixis and Invenra Expand Collaboration to Discover and Develop Novel Biologics in Oncology
2021-08-05 20:05 ET
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-05 12:00 ET
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2021-07-22 20:05 ET
Exelixis to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021
2021-07-08 20:05 ET
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
2021-06-28 05:00 ET
Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
2021-06-18 12:00 ET
Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence
2021-06-14 12:00 ET
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
2021-06-07 12:00 ET
Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
2021-06-04 13:00 ET
Exelixis Announces Positive Phase 2 Results for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma at ASCO 2021
2021-06-04 13:00 ET
Exelixis Announces Consistent Efficacy Benefits Across Subgroups of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-06-04 13:00 ET
Exelixis Announces Quality-Adjusted Survival Benefit Demonstrated in Analysis of Phase 3 CheckMate -9ER Trial of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) in Patients with Previously Untreated Advanced Renal Cell Carcinoma
2021-05-26 20:15 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
2021-05-24 20:05 ET
Exelixis Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
2021-05-06 20:05 ET
Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update
2021-05-04 12:00 ET
Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma’s First-in-Class Humanized Antibody Program Against a Novel Oncology Target
2021-04-27 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
2021-04-22 20:05 ET
Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021
2021-04-05 12:00 ET
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
2021-03-31 05:01 ET
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-03-30 12:00 ET
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
2021-03-18 12:00 ET
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma
2021-03-08 13:00 ET
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
2021-02-26 11:30 ET
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-02-25 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
2021-02-25 13:00 ET
Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
2021-02-19 21:07 ET
Exelixis to Webcast Virtual Fireside Chat as Part of the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021
2021-02-13 18:00 ET
Exelixis Highlights Positive Results for CABOMETYX® (cabozantinib) in Patients with Metastatic Papillary Renal Cell Carcinoma in SWOG S1500/PAPMET Study at ASCO GU
2021-02-12 22:15 ET
Exelixis Announces Final Phase 1 Results from Clinical Trial Sponsored by the National Cancer Institute at ASCO GU for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Patients with Refractory Metastatic Genitourinary Tumors
2021-02-10 21:05 ET
Exelixis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
2021-02-09 21:08 ET
Exelixis to Host Investor Briefing to Discuss Data Presented at the American Society of Clinical Oncology's 2021 Genitourinary Cancers Symposium
2021-02-08 22:00 ET
Exelixis Announces Positive Findings at ASCO GU for CABOMETYX® (cabozantinib) in Patients with Brain Metastases from Renal Cell Carcinoma
2021-02-08 22:00 ET
OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial
2021-02-04 21:05 ET
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 11, 2021
2021-02-01 13:00 ET
Exelixis and Adagene Enter into Collaboration and License Agreement to Develop Novel Masked Antibody-Drug Conjugate Therapies with Improved Safety and Efficacy Profiles
2021-01-27 21:05 ET
Exelixis to Release Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 10, 2021
2021-01-25 13:00 ET
Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors
2021-01-22 18:10 ET
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
2021-01-10 21:00 ET
Exelixis Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
2021-01-04 21:05 ET
Exelixis to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021
2020-12-21 12:30 ET
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
2020-12-16 13:00 ET
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
2020-12-07 13:00 ET
Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors
2020-12-02 13:00 ET
Exelixis In-Licenses Iconic Therapeutics’ Tissue Factor-Targeting Antibody-Drug Conjugate Ahead of Planned Investigational New Drug Application
2020-11-27 13:00 ET
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
2020-11-23 22:30 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
2020-11-05 21:05 ET
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update
2020-11-02 21:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November
2020-10-27 05:02 ET
Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal Cell Carcinoma in Japan
2020-10-26 12:00 ET
Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors
2020-10-22 20:05 ET
Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020
2020-10-19 10:59 ET
U.S. Food and Drug Administration Accepts for Priority Review Applications for OPDIVO® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Advanced Renal Cell Carcinoma
2020-10-09 07:02 ET
Exelixis and Aurigene Announce That Promising Preclinical Data to Be Presented at the ENA Symposium Support the Clinical Development of a Novel CDK7 Inhibitor
2020-10-09 07:01 ET
Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor
2020-09-21 14:20 ET
Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
2020-09-19 16:30 ET
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial
2020-09-15 12:00 ET
Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors
2020-09-14 12:00 ET
Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
2020-09-08 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September
2020-09-08 12:05 ET
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
2020-09-08 12:01 ET
Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology
2020-08-24 12:00 ET
Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma
2020-08-06 20:05 ET
Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-29 20:05 ET
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
2020-07-20 12:00 ET
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma
2020-06-30 12:00 ET
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer
2020-06-18 20:05 ET
Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020
2020-06-11 12:00 ET
Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer
2020-06-03 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
2020-05-13 21:00 ET
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
2020-05-06 20:05 ET
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
2020-05-05 20:05 ET
Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
2020-04-21 20:05 ET
Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020
2020-04-20 10:59 ET
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma
2020-04-08 20:05 ET
Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020
2020-03-25 07:01 ET
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
2020-03-02 21:05 ET
Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors
2020-02-26 21:05 ET
Exelixis Announces Webcasts of Investor Conference Presentations in March
2020-02-25 21:06 ET
Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer
2020-02-25 21:05 ET
Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-02-12 21:05 ET
Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020
2020-02-10 22:00 ET
Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
2020-02-06 21:05 ET
Exelixis Announces Webcasts of Investor Conference Presentations in February
2020-01-29 07:01 ET
Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma
2020-01-24 12:30 ET
Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
2020-01-12 21:00 ET
Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance
2020-01-07 21:05 ET
Exelixis to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020
2020-01-07 12:30 ET
Exelixis Further Expands Prostate Cancer Cohort in Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Atezolizumab in Patients with Advanced Solid Tumors
2019-12-19 12:00 ET
Exelixis Enters into a Clinical Collaboration for Three Phase 3 Combination Trials for Patients with Advanced Solid Tumors
2019-12-13 06:02 ET
Exelixis Announces Positive Results From IMspire150, the Phase 3 Trial of Atezolizumab Plus Cotellic and Vemurafenib in People With Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma
2019-11-26 21:06 ET
Exelixis Announces Webcasts of Investor Conference Presentations in December
2019-11-12 21:05 ET
Exelixis to Present at the Stifel 2019 Healthcare Conference on November 19, 2019
2019-11-12 13:02 ET
Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Patients With Previously Treated Advanced Hepatocellular Carcinoma
2019-11-08 01:01 ET
Exelixis’ Collaborator Daiichi Sankyo Announces Positive Results From Phase 3 Pivotal Trial of Esaxerenone in Patients With Diabetic Nephropathy
2019-10-30 20:05 ET
Exelixis Announces Third Quarter 2019 Financial Results and Provides Corporate Update
2019-10-16 20:05 ET
Exelixis to Release Third Quarter 2019 Financial Results on Wednesday, October 30, 2019
2019-09-25 20:05 ET
Exelixis to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019
2019-07-31 20:06 ET
Exelixis Announces Second Quarter 2019 Financial Results and Provides Corporate Update
2019-07-31 20:05 ET
Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer

SEC forms

Show financial reports only

SEC form 10
2024-04-30 16:32 ET
Exelixis published news for 2024 q1
SEC form 8
2024-04-30 16:12 ET
Exelixis published news for 2024 q1
SEC form 8
2024-04-30 16:12 ET
Exelixis reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
Exelixis published news for 2024 q1
SEC form 10
2024-02-06 00:00 ET
Exelixis reported for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Exelixis published news for 2023 q4
SEC form 10
2023-11-01 16:16 ET
Exelixis reported for 2023 q3
SEC form 8
2023-11-01 16:08 ET
Exelixis published news for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Exelixis published news for 2023 q3
SEC form 10
2023-08-01 16:13 ET
Exelixis reported for 2023 q2
SEC form 6
2023-08-01 16:11 ET
Exelixis published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Exelixis published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Exelixis published news for 2023 q2
SEC form 6
2023-07-24 16:41 ET
Exelixis published news for 2023 q2
SEC form 6
2023-06-05 16:35 ET
Exelixis published news for 2023 q1
SEC form 6
2023-06-02 21:50 ET
Exelixis published news for 2023 q1
SEC form 6
2023-06-02 21:50 ET
Exelixis published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Exelixis published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Exelixis reported for 2023 q1
SEC form 6
2023-04-13 16:26 ET
Exelixis published news for 2023 q1
SEC form 6
2023-03-22 16:36 ET
Exelixis published news for 2022 q4
SEC form 6
2023-03-20 07:04 ET
Exelixis published news for 2022 q4
SEC form 10
2023-02-07 16:22 ET
Exelixis reported for 2022 q4
SEC form 6
2023-02-07 16:09 ET
Exelixis published news for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Exelixis reported for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Exelixis reported for 2022 q4
SEC form 6
2023-01-09 16:15 ET
Exelixis published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Exelixis published news for 2022 q4
SEC form 6
2022-12-23 20:15 ET
Exelixis published news for 2022 q3
SEC form 6
2022-12-15 17:17 ET
Exelixis published news for 2022 q3
SEC form 10
2022-11-01 16:16 ET
Exelixis reported for 2022 q3
SEC form 6
2022-11-01 16:12 ET
Exelixis published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Exelixis reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Exelixis reported for 2022 q3
SEC form 6
2022-09-02 16:20 ET
Exelixis published news for 2022 q2
SEC form 10
2022-08-09 16:24 ET
Exelixis reported for 2022 q2
SEC form 6
2022-08-09 16:11 ET
Exelixis published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Exelixis reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Exelixis reported for 2022 q2
SEC form 6
2022-08-05 21:50 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:48 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:45 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:44 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:43 ET
Exelixis published news for 2022 q2
SEC form 6
2022-07-19 17:28 ET
Exelixis published news for 2022 q2
SEC form 6
2022-06-01 20:28 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:23 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:19 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:13 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:12 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:11 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:24 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:19 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:15 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:07 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:03 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 17:05 ET
Exelixis published news for 2022 q1
SEC form 10
2022-05-10 16:10 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-10 16:08 ET
Exelixis published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Exelixis reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Exelixis reported for 2022 q1
SEC form 6
2022-04-14 08:48 ET
Exelixis published news for 2022 q1
SEC form 6
2022-04-13 16:27 ET
Exelixis published news for 2022 q1
SEC form 6
2022-02-23 17:23 ET
Exelixis published news for 2021 q4
SEC form 10
2022-02-18 17:05 ET
Exelixis published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2022-02-17 16:20 ET
Exelixis published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2022-02-14 21:01 ET
Exelixis published news for 2021 q4
SEC form 6
2022-01-10 16:30 ET
Exelixis published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2021-12-17 16:11 ET
Exelixis published news for 2021 q3
SEC form 10
2021-11-02 16:18 ET
Exelixis published news for 2021 q3
SEC form 6
2021-11-02 16:11 ET
Exelixis published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Exelixis published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Exelixis published news for 2021 q3
SEC form 10
2021-08-05 16:19 ET
Exelixis published news for 2021 q2
SEC form 6
2021-08-05 16:14 ET
Exelixis published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Exelixis published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Exelixis published news for 2021 q2
SEC form 6
2021-06-21 17:14 ET
Exelixis published news for 2021 q1
SEC form 6
2021-06-21 17:08 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-27 17:03 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-11 17:04 ET
Exelixis published news for 2021 q1
SEC form 10
2021-05-06 16:30 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-06 16:18 ET
Exelixis published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Exelixis published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Exelixis published news for 2021 q1
SEC form 6
2021-04-15 09:05 ET
Exelixis published news for 2021 q1
SEC form 6
2021-03-05 17:11 ET
Exelixis published news for 2020 q4
SEC form 6
2021-03-03 16:34 ET
Exelixis published news for 2020 q4
SEC form 10
2021-02-10 20:48 ET
Exelixis published news for 2020 q4
SEC form 6
2021-02-10 16:14 ET
Exelixis published news for 2020 q4
SEC form 6
2021-02-05 17:12 ET
Exelixis published news for 2020 q4
SEC form 6
2021-01-11 16:07 ET
Exelixis published news for 2020 q4
SEC form 10
2020-11-05 16:21 ET
Exelixis published news for 2020 q3
SEC form 6
2020-11-05 16:14 ET
Exelixis published news for 2020 q3